S
ildenafil (Viagra, Pfizer, New York, NY), a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5, is now widely used in the treatment of erectile dysfunction in men. 1 The hemodynamic effects of sildenafil have been described in healthy men 2 and in both men and women with established cardiovascular disease, 3, 4 as well as in men with erectile dysfunction taking concomitant antihypertensive medication. 5, 6 As greater clinical experience is gained with the use of sildenafil, there is increasing interest in application of the drug to special populations, focusing on the unique vasodilator properties of the compound. There are now data suggesting that sildenafil is well tolerated in adult men with documented severe coronary artery disease 3 and in those taking vasodilators. 5, 6 Katz et al 4 have furthermore demonstrated improved brachial artery flow-mediated dilation (FMD) with escalating doses of sildenafil in patients with chronic heart failure. These vasodilator responses suggest that sildenafil may in fact have beneficial effects in a variety of vascular disorders, including hypertension (HTN).
Although we frequently have prescribed sildenafil for the treatment of erectile dysfunction in our male cardiac transplant recipients (CTR), there are no data describing the vascular effects of sildenafil in this special population. Cardiac transplant recipients often have refractory HTN, and frequently require numerous antihypertensive agents, including vasodilators, to control their blood pressure (BP). 7 They also experience cardiac denervation, which often limits circulatory adjustments to changes in arterial BP. We therefore sought to investigate the effects of sildenafil on vascular function, including wave reflection properties and peripheral endothelial function, in a typical group of hypertensive men taking antihypertensive medication after cardiac transplantation.
Methods

Study Population
The present study was a pilot investigation of adult male volunteers currently followed by our heart transplant program. Medically stable patients Ն3 months after transplant with a history of chronic post-transplant HTN were screened. All patients were taking one or more antihypertensive medications at the time of the study, and control of HTN was considered adequate based on measurements of brachial arterial cuff BP. The project was reviewed and approved by the local institutional review board, and all patients gave informed consent to participate in the study. Patients were in a fasting post-absorptive state at the time of the study, although they were instructed to continue to take their usual morning antihypertensive and antirejection medications, which should have been near their peak plasma concentrations at the time of the study.
Patients were placed supine in a quiet, temperaturecontrolled room and after a 15-min rest period, underwent duplicate measurements of heart rate, brachial cuff BP, and analysis of the radial arterial pulse wave. Radial arterial pulse wave analysis was performed in the dominant arm. Brachial arterial cuff BP was determined by an automated digital oscillometric sphygmomanometer (Omron, model HEM-739AC, Vernon Hills, IL). An aortic arterial pressure waveform was derived from the measured radial artery pulse waveform using applanation tonometry and a high fidelity ultrasound transducer (SPC-301, Millar Instruments, Houston, TX). A central aortic pressure wave was synthesized from the radial artery wave using the SphygmoCor device (AtCor Medical, Sydney, Australia) and a generalized transfer function, and various components of the wave were automatically calculated. Previous reports have confirmed the reproducibility 8 and reliability 9 of the SphygmoCor system for obtaining central aortic pressure waveforms. Aortic augmentation index (AI a ) was defined as the ratio of reflected wave amplitude and pulse pressure, or AI a ϭ (P s Ϫ P i )/(P s Ϫ P d ) where P s ϭ peak systolic pressure, P d ϭ end-diastolic pressure, and P i ϭ an inflection point marking the beginning upstroke of the reflected pressure wave. 10 Because heart rate is known to affect AI a , and our patients had elevated resting heart rates due to cardiac denervation, AI a was determined at both the intrinsic heart rate and at a reference heart rate of 75 beats/ min. Left ventricular ejection time (LVET) was measured from end-diastolic pressure to the trough of the dicrotic notch in the radial arterial pressure wave. Travel time, ⌬t p , of the forward traveling pressure wave from the heart to the major reflection site and back was measured as the time differential between P d and P i . Time duration of the reflected wave, ⌬t r , was taken as the difference between LVET and ⌬t p . Left ventricular tension time index, a marker of myocardial oxygen demand, was estimated as the integral of aortic pressure and time during systole.
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Brachial artery FMD was determined in the contralateral arm after release of a 5-min transient brachial artery occlusion in the upper arm using high-resolution ultrasound (ATL/Phillips Medical Systems model 800, Bothell, WA). Arterial internal diameter was measured at enddiastole from the anterior to the posterior intimal images and FMD calculated as the percent increase in diameter from baseline to the diameter measured at 60 sec after release of the occlusion. Five minutes after baseline measurements were collected, patients were given 50 mg of oral sildenafil. Repeat measurements of brachial artery cuff BP, heart rate, and the radial artery pressure waveform were collected every 15 min for a total of 60 min after dose. A single repeat determination of brachial artery FMD was made at 45 min after dose. The brachial artery FMD results were compared with an age-and gendermatched historic control group of 13 randomly selected patients free of cardiovascular disease, studied in the same laboratory under similar conditions. Data are expressed as mean Ϯ standard deviation. Changes from baseline values were tested using two-tailed standard Student t test for paired samples and a P value Ͻ .05 was considered statistically significant.
Results
Fifteen adult male CTR participated in the study, with an average age of 55 Ϯ 10 years. Patients were an average of 38 months after transplantation (range, 4 to 127 months) and were all taking one or more antihypertensive medications. The average number of antihypertensive drugs taken was 2.4 Ϯ 0.9 (range, 1 to 5 medications/patient). Thirteen of the 15 patients had hyperlipidemia necessitating drug therapy and 4 patients were diabetic. Patients were each taking a minimum of two antirejection medications.
Resting heart rate was 92 Ϯ 11 beats/min and did not change after sildenafil administration. Significant reductions were noted, however, in both peripheral and central arterial BP that were obvious at 15 min, reached a maximum at 30 to 45 min, and continued throughout the study period of 60 min. Significant reductions were noted in brachial systolic, mean, diastolic, and pulse pressure with sildenafil (P Ͻ .01 for each comparison) ( Table 1 ). The absolute reduction in brachial artery BP with sildenafil ranged from 3 to 19 mm Hg for systolic pressure (average 10 mm Hg) and from 1 to 7 mm Hg for diastolic pressure (average 4 mm Hg). Despite the continuation of usual antihypertensive medications, no patient became hypotensive with sildenafil or had any observed adverse reaction.
Central aortic pressure was also substantially reduced with sildenafil use and was reduced to a greater extent than brachial BP (Table 1) . Average aortic systolic pressure was reduced by 13 mm Hg as compared to a 10 mm Hg reduction in average brachial artery systolic pressure. Likewise, aortic pulse pressure was reduced by 6 mm Hg as compared to a 3 mm Hg reduction in brachial pulse pressure.
Central aortic AI a , a measure of wave reflection intensity, also declined significantly with sildenafil use (Table  1) . When AI a was referenced to a heart rate of 75 beats/ min, the reduction was even more pronounced. Sildenafil increased the travel time (⌬t p ) of the reflected aortic pressure wave to and from the periphery, thereby delaying return of the reflected wave to the heart. This increase in ⌬t p resulted in a reduction in the amplitude of the reflected pressure wave (P s Ϫ P i ) and in AI a . The amplitude of the forward traveling pressure wave (P i Ϫ P d ) was also substantially reduced with sildenafil. Combined reduction in both forward and reflected aortic pressure waves resulted in a substantial reduction in tension time index, a marker of left ventricular systolic stress and myocardial oxygen demand. The LVET increased after sildenafil administration with the maximal effect occurring somewhat later than the maximal reduction in arterial pressure. Because both LVET and pressure wave travel time increased, the systolic duration of the reflected wave, ⌬t r , did not change.
Baseline brachial artery FMD was 5.4% Ϯ 0.9%, indicating impaired endothelial function in our group of CTR as compared to an age-and gender-matched control group of 13 patients without cardiovascular disease (control group FMD, 7.1% Ϯ 2.5%; P Ͻ .001). A significant improvement in brachial artery FMD was noted 45 min after sildenafil administration, with a post-drug FMD value similar to that of the control population (Table 1) .
Discussion
This pilot investigation demonstrates that low-dose oral sildenafil is well tolerated in adult male CTR under active treatment for systemic HTN. No patient became hypotensive with the use of sildenafil despite continuation of background antihypertensive medication. The average maximum reductions in brachial systolic and diastolic pressure with sildenafil were similar to values previously reported in patients with cardiovascular disease, 3 but less than that observed in a group of hypertensive men with erectile dysfunction taking antihypertensive medication. 6 This may be due to the fact that baseline brachial BP and augmented pressure were higher in those previous studies than was noted in our patients before administration of sildenafil. Previous studies have shown that, although CTR with chronic post-transplant HTN are on antihypertensive medication, they still have a substantially high AI a , indicating early return of reflected waves to the central aorta, which augments pressure during systole. 12 These changes in wave reflection properties result in an increase in left ventricular afterload, myocardial mass, and myocardial oxygen demand. 13 Although all patients in our study were taking antihypertensive medication, the baseline AI a was abnormally high, indicating elevated wave reflection amplitude. Therefore, although these patients were believed to have "controlled" post-transplant HTN based on brachial cuff BP measurement, they still had a significantly abnormal AI a as determined by arterial pulse wave analysis. Sildenafil appears to substantially improve this marker of arterial wave reflection intensity when added to baseline antihypertensive therapy, and likewise improves endothelial function. Pulse pressure was also significantly reduced both centrally and in the periphery with sildenafil. Pulse pressure is now recognized to be an important marker of cardiovascular risk, and would ideally be lowered in populations like CTR, who have a high baseline risk for adverse cardiovascular events.
Although several studies have investigated the effects of sildenafil on standard hemodynamics, [2] [3] [4] [5] only one study has investigated the effects of sildenafil on wave reflections. 6 In that study in men with erectile dysfunction taking antihypertensive medication, oral sildenafil (50 mg) caused a delay (increased ⌬t p ) in the return of the reflected wave to the central aorta and thus reduced its amplitude (P s Ϫ P i ), indicating a decreased arterial pulse wave velocity. Because vasoactive drugs have little direct effect on large elastic arteries, the wave reflection action of sildenafil is likely confined to the muscular arteries. Like sildenafil, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and nitrates decrease reflected wave amplitude and reduce aortic systolic and pulse pressure more than brachial cuff systolic and pulse pressure. 13, 14 Therefore, sildenafil appears to exhibit hemodynamic effects comparable to these commonly used vasodilators, especially nitroglycerin. The favorable effects of sildenafil on several measures of vascular function indicate that this novel compound may warrant further investigation for use as a chronic vasodilator in CTR with chronic post-transplant HTN.
In conclusion, the results of this study indicate that sildenafil reduces central aortic augmentation index and BP and improves endothelial function in hypertensive CTR. This action on wave reflection properties implies that sildenafil reduces arterial pulse wave velocity and causes the reflected wave to be delayed in returning to the heart. This delay in arrival of the reflected wave reduces its amplitude, decreases systolic and pulse pressure, and reduces LV afterload and myocardial oxygen demand. The wave reflection property indices in this study were obtained using pulse wave analysis and a generalized transfer function that may be subject to varying degree of inaccuracy according to some investigators, [15] [16] [17] but not others. 9, 18 The report by Hope et al 17 suggested that generalized transfer functions may not be universally applicable across all waveform parameters of potential interest, and gender-specific transfer functions may be more appropriate. The accuracy of the generalized transfer function in our study may be improved, however, as all the patients in the study were men.
